Literature DB >> 27095017

Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms.

Emily B Nuechterlein1, Lisong Ni2, Edward F Domino3, Jon-Kar Zubieta4.   

Abstract

This study investigates differences in μ-opioid receptor mediated neurotransmission in healthy controls and overnight-abstinent smokers, and potential effects of the OPRM1 A118G genotype. It also examines the effects of smoking denicotinized (DN) and average nicotine (N) cigarettes on the μ-opioid system. Positron emission tomography with (11)C-carfentanil was used to determine regional brain μ-opioid receptor (MOR) availability (non-displaceable binding potential, BPND) in a sample of 19 male smokers and 22 nonsmoking control subjects. Nonsmokers showed greater MOR BPND than overnight abstinent smokers in the basal ganglia and thalamus. BPND in the basal ganglia was negatively correlated with baseline craving levels and Fagerström scores. Interactions between group and genotype were seen in the nucleus accumbens bilaterally and the amygdala, with G-allele carriers demonstrating lower BPND in these regions, but only among smokers. After smoking the DN cigarette, smokers showed evidence of MOR activation in the thalamus and nucleus accumbens. No additional activation was observed after the N cigarette, with a mean effect of increases in MOR BPND (i.e., deactivation) with respect to the DN cigarette effects in the thalamus and left amygdala. Changes in MOR BPND were related to both Fagerström scores and changes in craving. This study showed that overnight-abstinent smokers have lower concentrations of available MORs than controls, an effect that was related to both craving and the severity of addiction. It also suggests that nicotine non-specific elements of the smoking experience have an important role in regulating MOR-mediated neurotransmission, and in turn modulating withdrawal-induced craving ratings.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  A118G; OPRM1; PET; Smoking; [11C]-Carfentanil

Mesh:

Substances:

Year:  2016        PMID: 27095017      PMCID: PMC4891463          DOI: 10.1016/j.pnpbp.2016.04.006

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  42 in total

1.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

Review 2.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

3.  Reinforcing effects of nicotine and non-nicotine components of cigarette smoke.

Authors:  Jed E Rose; Al Salley; Frederique M Behm; James E Bates; Eric C Westman
Journal:  Psychopharmacology (Berl)       Date:  2010-04-01       Impact factor: 4.530

Review 4.  The reward circuit: linking primate anatomy and human imaging.

Authors:  Suzanne N Haber; Brian Knutson
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 5.  Endogenous opioids and smoking: a review of progress and problems.

Authors:  O F Pomerleau
Journal:  Psychoneuroendocrinology       Date:  1998-02       Impact factor: 4.905

Review 6.  The amygdala and emotion.

Authors:  M Gallagher; A A Chiba
Journal:  Curr Opin Neurobiol       Date:  1996-04       Impact factor: 6.627

7.  Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.

Authors:  Marta Peciña; Tiffany Love; Christian S Stohler; David Goldman; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2014-10-13       Impact factor: 7.853

8.  Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain.

Authors:  K E Davenport; A A Houdi; G R Van Loon
Journal:  Neurosci Lett       Date:  1990-05-18       Impact factor: 3.046

9.  The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor.

Authors:  Thomas Kroslak; K Steven Laforge; Robert J Gianotti; Ann Ho; David A Nielsen; Mary Jeanne Kreek
Journal:  J Neurochem       Date:  2007-10       Impact factor: 5.372

10.  Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers.

Authors:  Hiroto Kuwabara; Stephen J Heishman; James R Brasic; Carlo Contoreggi; Nicola Cascella; Kristen M Mackowick; Richard Taylor; Olivier Rousset; William Willis; Marilyn A Huestis; Marta Concheiro; Gary Wand; Dean F Wong; Nora D Volkow
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

View more
  13 in total

1.  The effects of alcoholism and smoking on advanced cancer patients admitted to an acute supportive/palliative care unit.

Authors:  Sebastiano Mercadante; Claudio Adile; Patrizia Ferrera; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2017-02-16       Impact factor: 3.603

2.  Tobacco Smoking and Brain Endogenous Opioid Release: More Than Nicotine Alone.

Authors:  Edward F Domino; Mika Hirasawa-Fujita
Journal:  Nicotine Tob Res       Date:  2019-05-21       Impact factor: 4.244

3.  Independent association of tobacco use with opioid use disorder in patients of European ancestry with chronic non-cancer pain.

Authors:  Martin D Cheatle; Mary Falcone; Lara Dhingra; Caryn Lerman
Journal:  Drug Alcohol Depend       Date:  2020-02-14       Impact factor: 4.492

4.  Marijuana and Prescription Pain Reliever Use among Cigarette Smokers.

Authors:  Rachel L Goldberg; Janine K Cataldo
Journal:  J Psychoactive Drugs       Date:  2018-08-17

Review 5.  Endogenous opioid system: a promising target for future smoking cessation medications.

Authors:  Haval Norman; Manoranjan S D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

6.  Neurobiological Considerations for Tobacco Use Disorder.

Authors:  Megha Chawla; Kathleen A Garrison
Journal:  Curr Behav Neurosci Rep       Date:  2018-10-30

Review 7.  Neuroimaging of reward mechanisms in Gambling disorder: an integrative review.

Authors:  Luke Clark; Isabelle Boileau; Martin Zack
Journal:  Mol Psychiatry       Date:  2018-09-13       Impact factor: 15.992

Review 8.  Positron emission tomography imaging of endogenous mu-opioid mechanisms during pain and migraine.

Authors:  Alexandre F DaSilva; Jon-Kar Zubieta; Marcos F DosSantos
Journal:  Pain Rep       Date:  2019-08-07

9.  Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.

Authors:  Hassan Jassar; Thiago D Nascimento; Niko Kaciroti; Marcos F DosSantos; Theodora Danciu; Robert A Koeppe; Yolanda R Smith; Marcelo E Bigal; Frank Porreca; Kenneth L Casey; Jon-Kar Zubieta; Alexandre F DaSilva
Journal:  Neuroimage Clin       Date:  2019-06-18       Impact factor: 4.881

Review 10.  Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

Authors:  Matthieu Colom; Benjamin Vidal; Luc Zimmer
Journal:  Front Mol Neurosci       Date:  2019-10-18       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.